The Next Generation of Weight-Loss Drugs Is Built for the Patients Who Quit Wegovy

Wegovy, Ozempic, and their peers produced double-digit weight loss in their pivotal trials. The next generation of injectable weight-loss drugs is being built for the patients who couldn't stay on them.

A meaningful share of patients prescribed those drugs stop within a year, most often because of nausea, vomiting, and stomach pain. The dropout is not just a quality-of-life problem. It is the gap between trial results and real-world health outcomes: a person who quits at month three never sees the cardiovascular or metabolic payoff the drugs are designed to deliver.

At the European Association for the Study of Diabetes (EASD) annual meeting in Milan this week, Zealand Pharma is presenting data from a Phase 2 trial, ZUPREME-1, designed around that gap. The trial randomized 485 adults to one of five weekly doses of petrelintide, an amylin analogue, over 42 weeks, alongside diet and physical-activity counseling (Zealand Pharma release). Petrelintide mimics amylin, a fullness hormone made in the pancreas, and works in parallel with the gut hormone GLP-1, the same pathway that Wegovy and its peers already target.

The sponsor reports that the highest-dose group lost up to 10.7% of body weight at week 42, against 1.7% on placebo under the trial's efficacy analysis, and 10.2% against 1.4% under the more conservative treatment-policy analysis (Zealand Pharma release). Both numbers fall short of the headline weight loss that GLP-1 drugs have produced in their own trials, but the cross-trial comparison is informal: ZUPREME-1 had no GLP-1 arm.

On tolerability, the sponsor reports generally mild gastrointestinal events, with no treatment discontinuations driven by vomiting or other GI events at the maximally effective 5.0 mg dose. That is a dose-specific sponsor claim—the published trial's adverse-event tables have not been independently reviewed to confirm this outcome. The Lancet Diabetes & Endocrinology lists ZUPREME-1 as published per the sponsor, but the article was not accessible to independent readers at the time of the conference (TIME). The trial's primary endpoint is at week 28, not week 42.

The data fit a broader pattern. Novo Nordisk's CagriSema, a combination of semaglutide, the active ingredient in Wegovy, with cagrilintide, an amylin analogue, is positioned as the company's next obesity candidate, and other amylin-class programs are advancing behind it. The shift is from one hormone pathway to two, and from chasing the highest possible weight loss to keeping more patients in treatment long enough to capture the downstream benefits.

The downstream payoff is the point. GLP-1 drugs lower the risk of heart attack, stroke, and kidney disease in patients with obesity and Type 2 diabetes, but only as long as patients keep taking them. A drug class that holds a 10% weight loss with a fraction of the dropout rate could plausibly deliver more real-world benefit than a marginally more effective drug that half of patients abandon in the first year.

Two questions remain open. The first is whether the tolerability signal holds in larger, longer Phase 3 trials with broader populations. Phase 2 dropout data is not real-world adherence, and the trial leader's optimistic framing, as TIME reports, is not independent clinical validation. The second is access. Pricing, insurance coverage, and prescribing patterns for any new amylin-based drug remain undecided, and the bottleneck these compounds are designed to fix is the same one that determines whether patients ever fill a second prescription.

The next generation of weight-loss drugs will be judged less on the headline weight-loss number than on the share of patients still taking them a year in.